Welcome to our dedicated page for ASTROTECH SEC filings (Ticker: ASTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astrotech Corporation filings document an instrumentation company organized around subsidiaries applying mass spectrometry and gas chromatography to security screening, narcotics detection, agriculture processing, industrial process control, breath analysis, and environmental testing. Results-related 8-K reports include operating updates for product lines such as TRACER 1000 and EN-SCAN.
The filing record also covers security-holder rights under the company's rights agreement, annual meeting voting matters, executive compensation and governance disclosures in proxy materials, officer changes, consulting arrangements, and transaction-related compensation plans. These disclosures describe ASTC's capital structure, board oversight, compensation framework, and material-event reporting obligations.
Stober Eric reported acquisition or exercise transactions in this Form 4 filing.
Astrotech Corp director Eric Stober received a grant of 6,006 shares of restricted common stock as equity compensation. The shares were awarded at no cash cost to him and vested 100% immediately on the grant date. After this grant, he directly holds a total of 16,337 Astrotech common shares. This filing reflects a routine stock award under the company’s 2021 Omnibus Equity Incentive Plan rather than an open-market purchase or sale.
MCFARLAND ROBERT N reported acquisition or exercise transactions in this Form 4 filing.
Astrotech Corp director Robert N. McFarland received a grant of 6,006 shares of common stock as equity compensation. The shares were issued as restricted stock under the Astrotech Corporation 2021 Omnibus Equity Incentive Plan at no stated purchase price.
According to the disclosure, 100% of these restricted shares vested immediately on the grant date, meaning McFarland gained full ownership and no ongoing vesting schedule applies to this award. Following the grant, he directly owns a total of 19,906 shares of Astrotech common stock.
Astrotech Corporation reports continued operating losses and shrinking cash as it invests in commercialization of its mass spectrometry platforms. For the three months ended March 31, 2026, revenue was $343,000, down from $534,000 a year earlier, with gross margin falling to 20% from 44% as some older consumables were sold below cost.
Operating expenses declined 14.2% to $3.5 million, but the company still posted a net loss of $3.8 million for the quarter and $11.2 million for the nine‑month period. Cash and cash equivalents were $2.7 million and short‑term investments $3.9 million, supporting working capital of about $9.5 million. Management believes these resources, plus operating cash flows and potential capital‑raising, will fund operations for at least the next 12 months, though substantial additional capital is expected to be needed for longer‑term growth.
Astrotech Corporation reported third-quarter fiscal 2026 results for the period ended March 31, 2026. Revenue for the quarter was $343 thousand compared with $534 thousand a year earlier, generating gross profit of $67 thousand. Operating expenses were $3.52 million, leading to a loss from operations of $3.45 million and a quarterly net loss of $3.77 million, versus $3.63 million in the prior-year quarter.
For the nine months ended March 31, 2026, revenue totaled $787 thousand and net loss was $11.16 million. Cash and cash equivalents were $2.68 million and short-term investments were $3.90 million as of March 31, 2026. Total assets were $16.17 million and total stockholders’ equity was $12.16 million, with an accumulated deficit of $262.03 million. Management highlighted continued cost-efficiency efforts while investing selectively in higher-return areas and advancing a sales pipeline across industrial, safety and trace detection markets.
Astrotech Corporation reported another loss-making quarter while maintaining a solid cash position. For the three months ended December 31, 2025, revenue fell to $148,000 from $261,000, as lower instrument and grant sales outweighed stronger consumables demand. Net loss was $3.9 million, slightly better than the prior year’s $4.0 million, driven mainly by lower operating expenses.
For the six-month period, revenue rose to $445,000 from $295,000, but the company still recorded a $7.4 million net loss. Operating cash outflow was $7.5 million, largely offset by $7.5 million of proceeds from short‑term investments, keeping cash at $3.1 million and short‑term investments at $7.0 million. Working capital stood at about $12.5 million, and management believes existing resources, together with potential equity offerings, can fund operations for at least the next 12 months.
The company continues to invest in commercializing its mass spectrometry platforms across security (TRACER 1000), agriculture (AgLAB 1000-D2), industrial process control (Pro-Control 1000-D2), and new environmental testing products under its EN-SCAN subsidiary. An S‑3 shelf registration was declared effective on January 30, 2026, but no securities have been sold under it yet. As of February 12, 2026, Astrotech had 1,758,953 common shares outstanding.
Astrotech Corporation reported results for its second quarter of fiscal 2026, which ended December 31, 2025. Revenue for the quarter was $148,000, down from $261,000 a year earlier, while the net loss narrowed slightly to $3.9 million from $4.0 million.
For the first six months of fiscal 2026, revenue rose to $445,000 from $295,000, but the net loss widened modestly to $7.4 million compared with $7.3 million in the prior-year period. As of December 31, 2025, Astrotech held $3.1 million in cash and cash equivalents and $7.0 million in short-term investments, with total stockholders’ equity of $15.5 million.
Astrotech Corporation has filed a shelf registration to offer up to $30,000,000 of securities, including common stock, preferred stock, debt securities, warrants and units, in one or more future offerings.
The company qualifies as a smaller reporting company and is subject to the “Baby Shelf Limitation,” which restricts primary offerings off this shelf to no more than one-third of its public float in any 12‑month period while its public float remains below $75 million. Based on a public float of approximately $5.92 million as of January 26, 2026, Astrotech currently may offer and sell up to about $1,974,354 of securities in primary offerings during a rolling 12‑month period.
Astrotech’s common stock trades on Nasdaq under the symbol “ASTC.” The company intends to use any net proceeds primarily for general corporate purposes, working capital, capital expenditures and potentially acquisitions or strategic investments, as described in future prospectus supplements.
Astrotech Corporation extended the duration of its stockholder rights plan. On December 12, 2025, the company entered into Amendment No. 3 to its Rights Agreement with Equiniti Trust Company, moving the Final Expiration Date of the rights to 5:00 p.m. New York City time on December 20, 2026, unless the date is further extended or the rights are earlier redeemed or exchanged under the agreement. All other terms of the rights plan remain the same.
The company also held its annual stockholder meeting on December 12, 2025, with 969,211 of 1,769,269 common shares entitled to vote represented in person or by proxy. Stockholders elected all director nominees and ratified the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, with 935,627 votes for, 20,631 against, and 12,952 withheld.
Astrotech Corp (ASTC) filed an initial Form 3 for officer Scott Bartley, who serves as Interim CFO, Treasurer and Secretary. The filing reports 0 shares of common stock beneficially owned and no derivative securities as of 10/27/2025. The form indicates it was filed by one reporting person.